trial

SV2 PET Imaging With [11C]APP311

NCTId NCT03995121
as of 2026-07-01
Add to landscapeMonitor thisAsk about this
at a glance
Phase — · Recruiting
Enrollment 250 (estimated)
Sponsored by Yale University
Primary completion 2026-12
Synthesized from structured facts only — each point cited above.

Design & status

Phase
—
Status
Recruiting
Enrollment
250 (estimated)
Study type
Observational
Allocation
—
Model
—
Masking
—
Start
2017-12-01
Primary completion
2026-12
Eligibility
ALL · 18 Years · 85 Years

Interventions & indications

Drugs
[11C]APP311

Sponsors

Yale UniversityLead Sponsor
National Institute on Drug Abuse (NIDA)Collaborator

Sites

1 total
New Haven, United States

Facts & assertions

4 sourced
Enrollment
250
Phase
NA
Primary Completion Date
2026-12
Status
RECRUITING
relationships
The graph out of here
drug
[11C]APP311
drug
lead_sponsor
Yale University
company
collaborator
National Institute on Drug Abuse (NIDA)
company
indication
Healthy
indication
Schizophrenia
indication
Schizophrenia and Other Psychotic Disorders
indication